Literature DB >> 6581839

Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients.

D A Clark, E N Dessypris, S B Krantz.   

Abstract

Thirty-seven patients with pure red cell aplasia (PRCA) were seen between 1966 and 1982. Ten patients had accompanying diseases described in association with PRCA, while the remainder had primary PRCA. All but two patients were treated with some form of immune manipulation, including corticosteroids, cytotoxic drugs, antithymocyte globulin, splenectomy, thymectomy, and plasmapheresis. Twenty-three patients (66%) had a remission induced by immunosuppression. In addition, there were 5 spontaneous remissions (14%). Cytotoxic drugs administered in combination with corticosteroids were the most effective form of treatment, producing 18/32 remissions (56%). Twelve of these remissions were in patients resistant to corticosteroids or in patients who had relapsed while taking them. Thirteen of the 23 patients in whom remissions were induced and one-fifth of the patients with spontaneous remissions have relapsed to date. However, with additional treatment, a second remission was induced in 10/13. Fifty-four percent of the patients with induced remissions remained transfusion-free during most of the follow-up period. Median survival in patients with primary PRCA was greater than 10 yr, whereas in patients with secondary PRCA, it was 4 yr. Infection was a major cause of morbidity and mortality. This study demonstrates the value of a variety of immunosuppressive treatments of patients with PRCA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6581839

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

2.  The efficacy of phlebotomy in a patient with prior pure red cell aplasia and iron overload secondary to transfusions.

Authors:  Massimo Franchini; Giuseppe Aprili; Gian Carlo Falezza
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

3.  Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C.

Authors:  Cheng-Shyong Chang; Sheng-Lei Yan; Hsuan-Yu Lin; Fu-Lien Yu; Chien-Yu Tsai
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

4.  Thymoma. Analysis of prognostic factors.

Authors:  M Sonobe; M Nakagawa; M Ichinose; N Ikegami; M Nagasawa; T Shindo
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-01

5.  PURE RED CELL APLASIA: A Case Report.

Authors:  Harsh Kumar; Rajat Kumar; J R Bhardwaj
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 6.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 7.  Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology.

Authors:  A Osama Gaber; Anthony P Monaco; James A Russell; Yvon Lebranchu; Mohamad Mohty
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

8.  Feline glucose-6-phosphate dehydrogenase cellular mosaicism. Application to the study of retrovirus-induced pure red cell aplasia.

Authors:  J L Abkowitz; R L Ott; J M Nakamura; L Steinmann; P J Fialkow; J W Adamson
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

9.  A case of pure red cell aplasia: follow-up on different immunosuppressive regimens.

Authors:  M Baldus; M Möller; H Walter; H Brass; W Queisser
Journal:  Clin Investig       Date:  1994-12

10.  Pure red-cell aplasia as the presenting feature of the carcionoid tumor of the thymus: case report.

Authors:  S M Petakov; N Suvajdzić; D M Petakov; D Sefer; S Ognjanović; D Macut; M Durović; T Isailović; D Subotić; J Stojsić; V Todorović; S Damjanović
Journal:  Med Oncol       Date:  2009-02-18       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.